Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

Autor(es)

Prada, Patricia O. ^[1] ; Saad, Mario J. A. ^[2]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas. UNICAMP

^[2] Univ Estadual Campinas. UNICAMP

• Tipo de documento: Artigo de Revisão
• Fonte: EXPERT OPINION ON INVESTIGATIONAL DRUGS; v. 22, n. 6, p. 751-763, JUN 2013.
• Citações Web of Science: 1

Resumo

Introduction: Some inhibitors of tyrosine kinase, as imatinib, erlotinib and sunitinib have antihyperglycemic effects but the mechanisms are not totally clear. Areas covered: It is well established that insulin resistance and beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present review will discuss the molecular mechanisms that account for insulin resistance and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors in these processes. Expert opinion: A better understanding of how these drugs improve the two most important mechanisms of DM2 associated with suggestions of clinical studies will lead to improve the treatment of this disease. (AU)

• Processo FAPESP: 12/10338-6 - Regulação das proteínas Clk2 e IKK epsilon em hipotálamo de camundongos obesos
• Beneficiário: Patrícia de Oliveira Prada
• Modalidade de apoio: Auxílio à Pesquisa - Regular